Please sign in to follow a disease.
Sensory peripheral neuropathy
MONDO:0002321Inflammation or degeneration of the sensory nerves.
Also known as: peripheral neuropathy of sensory nerve, peripheral sensory neuropathy, sensory nerve peripheral neuropathy
63 clinical trials for this condition and its sub-types, 4 tagged with Sensory peripheral neuropathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Sensory peripheral neuropathy
-
Hereditary sensory and autonomic neuropathy 52 trials · 54 incl. sub-types
13 sub-types
- Hereditary sensory and autonomic neuropathy type 1 0 trials · 2 incl. sub-types Sub-types →
- X-linked hereditary sensory and autonomic neuropathy with hearing loss 0 trials
- Cold-induced sweating syndrome - hyperthermia spectrum 0 trials Sub-types →
- Congenital insensitivity to pain with hyperhidrosis 0 trials
- Congenital insensitivity to pain-hypohidrosis syndrome 0 trials
- Hereditary sensory and autonomic neuropathy type 2 0 trials Sub-types →
- Hereditary sensory and autonomic neuropathy type 4 0 trials
- Hereditary sensory and autonomic neuropathy type 5 0 trials
- Hereditary sensory and autonomic neuropathy type 6 0 trials
- Hereditary sensory and autonomic neuropathy type 7 0 trials
- Hereditary sensory neuropathy X-linked 0 trials
- Neuropathy, hereditary sensory, atypical 0 trials
- Polyneuropathy-hand defect syndrome 0 trials
Most studied deeper sub-types
-
New drug combo takes on deadly brain tumors
Disease control OngoingThis early-stage study tests an experimental drug called AZD1390 combined with radiation therapy for people with glioblastoma or brain metastases. The main goal is to check safety and find the best dose. About 180 participants will receive different doses of AZD1390 alongside rad…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Cancer drug shows promise for rare blood vessel disorders in kids and young adults
Disease control OngoingThis study tests the drug alpelisib, already approved for some breast cancers, in people aged 2 months to 30 years with certain blood vessel growth disorders caused by PIK3CA or TIE2 gene changes. Participants take the drug for 2-3 years and attend up to 16 clinic visits to check…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise for stubborn cancers
Disease control OngoingThis study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…
Phase 2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control PausedThis study tests an oral drug called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or a high-risk bone marrow disorder (MDS) that have not responded to or returned after prior treatment. The goal is to find the safest and most effective dose and to see if the …
Phase 1/2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Painless eye drops could save sight in kids with brain tumors
Disease control OngoingThis study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard n…
Phase 2 • Sponsor: Benedetto Falsini • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill takes on Hard-to-Treat cancers in first human trial
Disease control OngoingThis early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…
Phase 1 • Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called pacritinib in people with advanced solid tumors (like breast cancer) that have a specific genetic change called 1q21.3 amplification. The goal is to see if the drug can shrink tumors or slow their growth. About 74 adults whose cancer has not respond…
Phase 1/2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New dissolving film may stop dangerous episodes in rare nerve disease
Symptom relief By invitation onlyThis study tests a medicated film placed under the tongue to quickly ease severe episodes (autonomic crises) in people with familial dysautonomia. The film contains dexmedetomidine, a drug that calms the body's stress response. Researchers will check if it reduces symptoms like h…
Phase 2 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC